Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets.
NLME
flunixin meglumine
non-steroidal anti-inflammatory
pain
swine
topical
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
04
2020
accepted:
21
07
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
3
10
2020
Statut:
epublish
Résumé
Castration and tail-docking of pre-wean piglets are common procedures that are known to induce pain and would benefit from pain mitigation. Flunixin meglumine (FM) is a non-steroidal anti-inflammatory drug currently approved in the United States for pyrexia in swine and lameness pain in cattle. The objective of this study was to establish the pharmacokinetic (PK) parameters resulting from intravenous (IV), intramuscular (IM), oral (PO) and transdermal (TD) administration of FM in pre-wean piglets. FM was administered to thirty-nine pre-wean piglets at a target dose of 2.2 mg/kg for IV and IM and 3.3 mg/kg for PO and TD route. Plasma was collected at twenty-seven time points from 0 to 9 days after FM administration and concentrations were determined using ultra-high performance liquid chromatography coupled with mass spectrometry (UPLC-MS). Pharmacokinetic data were analyzed using noncompartmental analysis (NCA) methods and nonlinear mixed-effects (NLME). Initial plasma concentration for IV (C
Identifiants
pubmed: 33005646
doi: 10.3389/fvets.2020.00586
pmc: PMC7485418
doi:
Types de publication
Journal Article
Langues
eng
Pagination
586Informations de copyright
Copyright © 2020 Kittrell, Mochel, Brown, Forseth, Hayman, Rajewski, Coetzee, Schneider, Ratliffe, Skoland and Karriker.
Références
Am J Med. 1999 May 31;106(5B):3S-12S
pubmed: 10390123
J Vet Pharmacol Ther. 2012 Apr;35 Suppl 1:39-43
pubmed: 22413790
Pharm Res. 2015 Jun;32(6):1931-46
pubmed: 25446774
J Anim Sci. 1973 Feb;36(2):259-63
pubmed: 4687085
J Vet Pharmacol Ther. 2004 Dec;27(6):441-53
pubmed: 15601439
Pharmacol Res. 2005 Oct;52(4):302-6
pubmed: 15939622
Comput Methods Programs Biomed. 2004 Oct;76(1):31-40
pubmed: 15313540
BMC Vet Res. 2013 Aug 13;9:165
pubmed: 23941181
Ther Deliv. 2011 May;2(5):643-72
pubmed: 21837267
Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1317-34
pubmed: 23834396
J Vet Pharmacol Ther. 2014 Dec;37(6):531-41
pubmed: 24731191
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e6
pubmed: 23835886
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):87-109
pubmed: 27884052
J Vet Pharmacol Ther. 2019 Jul;42(4):492-495
pubmed: 31197844
J Am Vet Med Assoc. 2017 Jun 1;250(11):1271-1274
pubmed: 28509650
J Vet Pharmacol Ther. 2002 Dec;25(6):460-3
pubmed: 12485352
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8
pubmed: 10377455
Front Vet Sci. 2019 Nov 07;6:385
pubmed: 31788483
J Vet Pharmacol Ther. 2018 Apr;41(2):171-183
pubmed: 29226975
J Vet Pharmacol Ther. 2018 Apr;41(2):314-323
pubmed: 29143334
J Vet Pharmacol Ther. 2004 Dec;27(6):415-25
pubmed: 15601437
J Vet Pharmacol Ther. 2004 Dec;27(6):455-66
pubmed: 15601440
J Vet Pharmacol Ther. 2019 Sep;42(5):530-540
pubmed: 31369157
Exp Toxicol Pathol. 2006 Nov;58(2-3):163-73
pubmed: 16859903
Pharm Res. 2016 Dec;33(12):2979-2988
pubmed: 27604892
Annu Rev Pharmacol Toxicol. 1992;32:185-209
pubmed: 1605567
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):625-635
pubmed: 27770596
Animals (Basel). 2017 Aug 22;7(8):
pubmed: 28829381
J Vet Pharmacol Ther. 2016 Dec;39(6):612-615
pubmed: 27121728
Front Vet Sci. 2019 Oct 17;6:363
pubmed: 31681816
Front Genet. 2018 Feb 13;9:40
pubmed: 29487615
J Vet Pharmacol Ther. 2006 Oct;29(5):437-40
pubmed: 16958790
J Anim Sci. 1995 Feb;73(2):381-6
pubmed: 7601768